VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients
Pharmaceutical Investing VBI Vaccines Announces Dosing of First Patient in Phase 1/2a Clinical Study of VBI-1901
Pharmaceutical Investing VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction
